Ten Years of EWAS

Epigenome‐wide association study (EWAS) has been applied to analyze DNA methylation variation in complex diseases for a decade, and epigenome as a research target has gradually become a hot topic of current studies. The DNA methylation microarrays, next‐generation, and third‐generation sequencing te...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Siyu, Tao, Junxian, Xu, Jing, Chen, Xingyu, Wang, Zhaoyang, Zhang, Nan, Zuo, Lijiao, Jia, Zhe, Chen, Haiyan, Sun, Hongmei, Yan, Yubo, Zhang, Mingming, Lv, Hongchao, Kong, Fanwu, Duan, Lian, Ma, Ye, Liao, Mingzhi, Xu, Liangde, Feng, Rennan, Liu, Guiyou, Project, The EWAS, Jiang, Yongshuai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529436/
https://www.ncbi.nlm.nih.gov/pubmed/34382344
http://dx.doi.org/10.1002/advs.202100727
Descripción
Sumario:Epigenome‐wide association study (EWAS) has been applied to analyze DNA methylation variation in complex diseases for a decade, and epigenome as a research target has gradually become a hot topic of current studies. The DNA methylation microarrays, next‐generation, and third‐generation sequencing technologies have prepared a high‐quality platform for EWAS. Here, the progress of EWAS research is reviewed, its contributions to clinical applications, and mainly describe the achievements of four typical diseases. Finally, the challenges encountered by EWAS and make bold predictions for its future development are presented.

Ejemplares similares